Loading…
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $99M | $83M | $-2M | 53.8% | 350.9% | -178.9% |
| 2024 | $24M | $-76M | $-106M | $-70M | -266.0% | -14.0% | 129.1% |
| 2023 | $27M | $-44M | $-46M | $-34M | -74.4% | 170.3% | 72.0% |
| 2022 | $10M | $-26M | $-27M | $-19M | -35.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 10.16 | 27.46 | 23.61 | 106.47 |
| Operating Revenue | - | 10.16 | 27.46 | 23.61 | 106.47 |
| Cost Of Revenue | - | 0.22 | 2.17 | 7.42 | 16.48 |
| Gross Profit | - | 9.94 | 25.29 | 16.20 | 89.99 |
| Operating Expense | - | 34.84 | 74.89 | 103.20 | 94.22 |
| Research And Development | - | 19.80 | 39.81 | 42.10 | 12.74 |
| Selling General And Administration | - | 15.04 | 34.31 | 54.87 | 77.62 |
| Total Expenses | - | 35.06 | 77.06 | 110.62 | 110.70 |
| Operating Income | - | -24.90 | -49.60 | -87 | -4.23 |
| Total Operating Income As Reported | - | -42.56 | -49.60 | -87 | -62.94 |
| EBITDA | - | -25.53 | -43.54 | -76.40 | 98.71 |
| Normalized EBITDA | - | -22.44 | -44.06 | -78.44 | 6.77 |
| EBIT | - | -26.47 | -44.55 | -82.79 | 94.66 |
| Interest Income | - | 1.51 | 4.54 | 2.17 | 6.95 |
| Interest Expense | - | 0.34 | 1.50 | 7.35 | 7.98 |
| Net Interest Income | - | 1.18 | 3.04 | -5.18 | -1.03 |
| Other Income Expense | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Interest Income Non Operating | - | 1.51 | 4.54 | 2.17 | 6.95 |
| Interest Expense Non Operating | - | 0.34 | 1.50 | 7.35 | 7.98 |
| Net Non Operating Interest Income Expense | - | 1.18 | 3.04 | -5.18 | -1.03 |
| Pretax Income | - | -26.80 | -46.05 | -90.14 | 86.68 |
| Tax Provision | - | -0.03 | 0 | 15.37 | 3.45 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0.43 | 3.66 |
| Net Income Continuous Operations | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income From Continuing And Discontinued Operation | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income From Continuing Operation Net Minority Interest | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Common Stockholders | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Including Noncontrolling Interests | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Normalized Income | - | -23.69 | -46.56 | -107.12 | -5.05 |
| Diluted NI Availto Com Stockholders | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Basic Average Shares | - | 34.49 | 35.45 | 46.25 | 55.31 |
| Diluted Average Shares | - | 34.49 | 35.45 | 46.25 | 57.26 |
| Reconciled Depreciation | - | 0.94 | 1.01 | 6.39 | 4.05 |
| Reconciled Cost Of Revenue | - | 0.22 | 1.94 | 7.26 | 16.29 |
| Total Unusual Items | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Total Unusual Items Excluding Goodwill | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Special Income Charges | - | -17.66 | 0 | 0 | 89.62 |
| Other Special Charges | 16.10 | 17.66 | - | - | - |
| Impairment Of Capital Assets | - | - | - | 0 | 58.71 |
| Restructuring And Mergern Acquisition | 0 | - | - | - | - |
| Gain On Sale Of Security | - | 14.58 | 0.52 | 2.04 | 2.33 |
| Depreciation Amortization Depletion Income Statement | - | - | 0.77 | 6.24 | 3.86 |
| Depreciation And Amortization In Income Statement | - | - | 0.77 | 6.24 | 3.86 |
| General And Administrative Expense | 8.70 | 15.34 | - | - | - |
| Other Gand A | 8.70 | 15.34 | - | - | - |
| Gain On Sale Of Ppe | - | - | - | 0 | 148.32 |
| Total Other Finance Cost | 0.15 | - | - | - | - |
| Otherunder Preferred Stock Dividend | 54.34 | 0 | - | - | - |
| Amortization | - | - | 0.77 | 6.24 | 3.86 |
| Amortization Of Intangibles Income Statement | - | - | 0.77 | 6.24 | 3.86 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Zevra Therapeutics, Inc.this co. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| SI-BONE, Inc. | SIBN | $660M |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 3.72 |
| -10.6% |
| - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Peer Median | - | -9.63 | 3.44 | -37.3% | -3.17 | |